# Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer

> **NCT01388790** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 40 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Cisplatin
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT01388790
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-08
- **Final completion:** 2013-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01388790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01388790, "Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01388790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*